Lv1
40 积分 2023-07-10 加入
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
13天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
3个月前
已关闭
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
3个月前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
3个月前
已完结
Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts
4个月前
已关闭
Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts
5个月前
已关闭
Estimands in Oncology Early Clinical Development: Assessing the Impact of Intercurrent Events on the Dose-Toxicity Relationship
6个月前
已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
6个月前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
7个月前
已完结
皖公网安备34019202002308
